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literature, Anti-D was selected over IVIG as the preferred agent
at Staten Island University Hospital. The objectives of this study
were to investigate how much IVIG was spared after implemen-
tation of this decision and determine the cost savings realized
when Anti-D is used in place of IVIG. METHODS: Literature
supporting the utilization of Anti-D in treatment of ITP was
presented by each of the key clinical faculty. The oncology phar-
macist screened and veriﬁed all IVIG orders for ITP patients.
Substitution with Anti-D was made for all Rh+ and non-
splenectomized patients. The quantity of IVIG spared was calcu-
lated by subtracting the amount dispensed before and after
implementation of the program. Savings realized were calculated
by determining the cost of a treatment course with IVIG and with
Anti-D for a 80 kg patient. RESULTS: A total of 904 and 130 g
of IVIG were administered during the ﬁrst and the second half
of 2006, respectively. Similarly, 220,000 and 376,000 units of
Anti-D were used during the same time periods. A treatment
course with IVIG (at 1 g/kg/day for two days) costs $8960
whereas a treatment course of Anti-D costs $4200 (at 75 ìg/kg).
Since the treatment of a 80 kg patient would require 160 g of
IVIG, the 774 g spared represent the amount necessary to treat
5 patients with IVIG. The sparing of 774 g of IVIG therefore
helped save $23,800. Also, 3 other courses were done with
Anti-D instead of IVIG yielding $14,280 in additional savings.
CONCLUSION: In 2006, the implementation of a therapeutic
substitution program at Staten Island University Hospital
making Anti-D the preferred agent over IVIG in the treatment of
ITP helped spare 774 grams of IVIG and saved $38,080.
PSY26
THE DIRECT MEDICAL COSTS ASSOCIATEDWITH
SUSPECTED (CONFIRMED AND NEGATIVE)
HEPARIN-INDUCEDTHROMBOCYTOPENIA
Nanwa N1, Mittmann N2, Knowles S2, Selby R2, Shear N1, Bucci C2,
Walker S1, Geerts W2
1University of Toronto,Toronto, ON, Canada, 2Sunnybrook Health
Sciences Centre,Toronto, ON, Canada
OBJECTIVE: Heparin-induced thrombocytopenia (HIT) is an
important adverse reaction associated with heparin utilization.
No previous studies have assessed the cost of suspected HIT or
examined HIT from a Canadian perspective. Therefore, the
objective of our study was to quantify the direct medical costs
associated with suspected and conﬁrmed HIT from a Canadian
hospital perspective. METHODS: A cost of illness analysis was
conducted on a population of consecutive patients with sus-
pected HIT during 2005. Suspected HIT was deﬁned by the
performance of a HIT enzyme-linked immunosorbent assay
(ELISA). Conﬁrmed HIT was deﬁned by one the following: 1)
positive serotonin release assay (SRA), 2) positive HIT ELISA
plus high clinical probability for HIT, or 3) strongly positive
HIT ELISA (optical density  1.0). Negative HIT was deﬁned
as a negative HIT ELISA or SRA result. Resource utilization
variables included: 1) HIT-safe anticoagulant use, 2) laboratory
tests, 3) diagnostic and surgical procedures, and 4) length of
stay (LOS) attributed to HIT. The average cost (2007 CAN$)
per case of conﬁrmed HIT, conﬁrmed HIT with thrombosis
(HITT), and negative HIT was calculated. Cost data was
obtained from hospital and provincial sources. RESULTS:
There were 110 suspected HIT cases (56 males: 54 females) in
2005. Two patients were excluded because their HIT status
could not be determined. Average LOS was 36  42 (range
3–244) days. There were 88 negative HIT cases, 8 with con-
ﬁrmed HIT, and 12 with conﬁrmed HITT. Patients with con-
ﬁrmed HITT incurred substantially greater average costs
($25,696, range $357–$145,217) than those with conﬁrmed
HIT ($3846, range $38–$14,258). The average cost of a nega-
tive HIT case was $115 (range $38–$4119). CONCLUSION:
This is the ﬁrst study to identify the costs associated with con-
ﬁrmed HIT, conﬁrmed HITT, and negative HIT. Suspected HIT
increases the costs of hospital care.
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OBJECTIVE: To examine literature published during the past ten
years describing the impact of obesity and obesity-related disease
on direct and indirect costs in Australia, Canada, France,
Germany, Italy, Spain, Sweden, the UK, and the US. METHODS:
A review of the medical literature published from 1997 to 2007
was conducted, including MEDLINE, EMBASE, Current
Contents Connect, and International Pharmaceutical Abstracts
databases; ISPOR abstracts; and data published by relevant gov-
ernmental agencies. RESULTS: A substantial portion of direct
costs related to obesity derive from treating comorbidities asso-
ciated with the condition (e.g., type 2 diabetes, cardiovascular
disease). Indirect costs, including those associated with reduced
work productivity, increased absenteeism, and premature death,
are signiﬁcant, with the majority arising from comorbid condi-
tions. Direct costs were greater for obese patients than for
normal-weight patients; morbid obesity was associated with dra-
matic cost increases. Estimates of direct costs as a percentage of
national health care expenditures were 5.7% for the US, and
ranged from 2% to 2.6% for Australia, Canada, Sweden, and the
UK. No estimates of indirect costs as a percentage of national
health care costs were identiﬁed. No studies involving direct or
indirect cost data collected since 1995 were identiﬁed for France,
Italy, or Spain. CONCLUSION: Obesity has a substantial eco-
nomic impact because of its high prevalence, association with
multiple chronic diseases, and increased levels of disability and
absenteeism. The lack of recent direct or indirect cost estimates in
several countries highlights the need for further work to describe
the global economic burden of obesity.
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OBJECTIVE: Conduct a systematic review of low back pain cost
of illness studies. METHODS: Medline was searched to uncover
studies about the direct or indirect costs of low back pain pub-
lished in English from 1997 to 2007. Data extracted for each
eligible study included study design, population, deﬁnition of low
back pain, methodology for estimating costs, year of data, and
estimates of direct, indirect, or total costs. RESULTS: The search
yielded 147 studies; 27 were deemed relevant. The studies
reported on data from Australia, Belgium, Japan, Korea, The
Netherlands, Sweden, the UK, and the US. Nine studies estimated
direct costs only, 9 indirect costs only, and 9 both direct and
indirect costs, from a societal (n = 18) or private insurer (n = 9)
perspective. Methodology used to derive both direct and indirect
cost estimates differed markedly among the studies. Among
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